PitchBook: 95+ investors put money into both Anthropic and OpenAI amid shifting norms; sources: Menlo, Lightspeed, and Iconiq each hold 1%-2% Anthropic stakes
Context & Ripple Effects
Anthropic’s investor base has expanded alongside its financing trajectory: Lightspeed was reported in talks for its 2025 round, and the company later completed a $65B Series H financing at a valuation above OpenAI’s reported figure. PitchBook’s count shows that capital is not sorting cleanly into one frontier-lab camp or the other.
The reported 1%-2% Anthropic positions for Menlo, Lightspeed and Iconiq are source-based and unconfirmed. Public reaction framed the overlap as a break from the venture-capital taboo against backing direct rivals.
First-order effects
- More than 95 investors hold positions in both Anthropic and OpenAI, giving each firm access to a substantially overlapping pool of venture relationships rather than distinct sponsor blocs.
- For Menlo, Lightspeed and Iconiq, the reported Anthropic stakes—if accurate—sit alongside exposure to OpenAI, making portfolio participation in the category more important than an exclusive lab bet.
Second-order effects
- Anthropic and OpenAI face less investor-driven pressure to differentiate through exclusivity, while competing for capital on commercial execution, valuation and liquidity prospects.
- The same firms can carry market intelligence and financing expectations across both labs, increasing the importance of governance boundaries when investors back rival frontier-model developers.
Third-order effects
- If cross-ownership persists, frontier AI funding is likely to become more concentrated among investors able to finance multiple capital-intensive labs, rather than divided into rival venture syndicates.
- A public-market pathway for major AI labs would extend that shift: investors can seek diversified exposure to the category while concentrating influence in a relatively small set of capital providers.
The trend: Frontier AI investing is moving from exclusive company sponsorship toward diversified, overlapping ownership across a small number of capital-intensive labs.